Back to News
Market Impact: 0.25
COMPASS Pathways plc Reports Third Quarter 2026 Financial Results and Business Highlights
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
COMPASS Pathways said its rolling New Drug Application submission is nearing completion and rolling review is underway. The company stated that it expects to file the final NDA submission in the next period, but the provided article text cuts off before specifying when.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.25
Ticker Sentiment
CMPS0.60
More News
- Stifel reiterates Compass Pathways stock rating on NDA progress
- Binance co-CEO Richard Teng says hackers used fake job interviews, AI tool to steal $6.3 billion in crypto 108511116
- AMD stock jumps 7% on earnings as data center revenue nearly doubles
- Marvell Technology could plunge on latest multibillion-dollar acquisition
- Disney Plans Thousands of Layoffs Companywide
- 5 things to watch on Election Day as Democrats push for control of Congress